A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

- Japanese participants aged 6 to 17 years at screening - Participants must have a weight of ≥ 15 kg - Diagnosis of chronic plaque psoriasis for at least 3 months prior to screening - Has moderate to severe plaque psoriasis at screening and baseline as defined by: - PASI score ≥ 12; and - BSA ≥ 10; and - sPGA ≥ 3 (moderate to severe) - Disease inadequately controlled by or contraindicated for ≥ 1 topical therapy for psoriasis - Candidate for systemic therapy or phototherapy

- Psoriasis flare or rebound within 4 weeks prior to screening - Evidence of skin conditions, other than psoriasis, that would interfere with clinical assessments - Other than psoriasis, history of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease - Prior history of suicide attempt at any time in the participant's lifetime prior to screening or baseline in the study, or major psychiatric illness requiring hospitalization within 3 years prior to signing the assent and informed consent - Guttate, erythrodermic, or pustular psoriasis at screening and baseline